BACKGROUND: Human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinomas (OPSCCs) demonstrate superior outcome compared with HPV-negative OPSCCs. The eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor, lymph node, metastasis (TNM) classification (TNM 2017) modifies OPSCC staging based on p16 positivity as a surrogate for HPV-driven disease. In p16-negative OPSCCs, lymph node (N) categories include extracapsular/extranodal extension (ECE); and, in p16-positive OPSCCs, N categories are based on the number of positive neck lymph nodes omitting ECE status.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is a malignancy arising from the epithelial lining the upper aerodigestive tract. In 2012, approximately 142,000 individuals worldwide (corresponding to 1% of all cases) suffered from pharyngeal cancer. 1 Today, the incidence rates have increased further by approximately 3.5% per year, and these increases are mainly attributable to the increased incidence of oropharyngeal squamous cell carcinoma (OPSCC). 2 Cancer Month 0, 2020
The main risk factors for developing OPSCC are tobacco use and excessive alcohol consumption. [3] [4] [5] [6] Although, in the Western world, tobacco use is (slowly) decreasing, especially among men, increases in the number of patients with OPSCC who are infected by oncogenic high-risk subtypes of the human papillomavirus (HPV) (namely, HPV type 16 [HPV16]) 7 have been observed in recent decades 2, [8] [9] [10] [11] [12] [13] and have been identified as an important risk factor for OPSCC, 14, 15 especially for OPSCC of the tonsils. 7, [16] [17] [18] The disease-free survival (DFS), tumor-specific survival (TSS), and overall survival (OS) of patients who have HPV-related OPSCC is superior compared with the survival of those who have HPV-negative OPSCC, because their cancer often is not etiologically linked to tobacco smoking or high rates of alcohol consumption. 13, [17] [18] [19] [20] [21] Consequently, HPV-related OPSCC is considered a separate entity that should be classified and treated in separate ways to optimize the balance between the treatment-related risk of organ dysfunction (like xerostomia, swallowing problems, and dysphagia) and patient outcome. 21, 22 The reliable identification of HPV-related OPSCC is possible with HPV-DNA detection and genotyping, followed either by the detection of the HPV early proteins E6 and E7 or by the detection of cancer-related HPV-RNA patterns characterized by the expression of mRNA encoding E6 and E7, and particularly the detection of E6*I. 23, 24 Because the neoplastic transformation of epithelial cells by HPV proteins E6 and E7 from high-risk oncogenic HPV subtypes (eg, HPV16) leads to the overexpression of p16 INK4A , it is possible to use p16-staining immunohistochemistry (IHC) to distinguish p16-positive, HPV-related (etiologic HPV-driven) OPSCC on one hand and p16-negative/ HPV-negative and only HPV16 DNA-positive tumors without transcription of viral genes on the other. Since p16 detection can be performed with standard techniques using formalin-fixed, paraffin-embedded specimens, is not specific for particular high-risk HPV subtypes and is considered reliable regarding the detec tion of HPV infection actively driving OPSCC; moreover, p16 staining is not that challenging as the detection of E6 and E7 mRNA (eg, E6*I), or of the more difficult-to-detect proteins E6 and E7 themselves, positive p16 status determined with IHC is widely accepted and routinely used as a surrogate marker for HPV-related OPSCC. [25] [26] [27] In 2017, the eighth edition of the American Joint Committee on Cancer (AJCC) cancer staging manual (tumor, lymph node, and metastasis [TNM] classification) (TNM 2017) was introduced and brought several changes to the staging of oropharyngeal cancers. 26 The most significant change in HNSCC staging compared with the seventh edition (TNM 2010) is the objective of separating HPV-related and HPV-negative OPSCC and staging of 2 separately handled entities, discriminating p16-positive and p16-negative OPSCC. 22, 26 Furthermore, the classification of lymph node status (N category) has changed and now differs between p16-positive and p16-negative OPSCC. Extracapsular extension (ECE) of disease-positive lymph nodes is considered a prognostic factor for poor OS in patients with p16-negative disease and now leads to upstaging to at least N2a (1 positive lymph node measuring <3 cm) and stage IVA disease or, otherwise, to stage IVB disease according to the newly introduced N3b category. 22, 26 In the pathologic staging of p16-positive OPSCC, however, ECE is not considered, and pathologic N (pN) categories in surgically treated patients are defined only by the number of positive lymph nodes (pN1, 1-4 positive lymph nodes; pN2, ≥5 positive lymph nodes) without a subdivision of N2 categories.
ECE has long been known for its association with a poor outcome, 28, 29 its detection after surgery (Op) defines the need for cisplatin-based postoperative radiochemotherapy (Op+PORCT), which improves outcomes. [29] [30] [31] Because the role of ECE in p16-positive OPSCC is not yet completely clear and outcomes may be influenced by HPV status, we were interested in: 1) the frequency of ECE in patients who have p16-positive OPSCC, 2) factors associated with ECE in p16-positive OPSCC, 3) the effect of HPV16 detection on positive ECE status, and 4) the effect of ECE with or without HPV16 on various outcome measures in patients who have p16-positive OPSCC.
MATERIALS AND METHODS

Patients and Pathologic Tumor Data
The tumor database of the Otolaryngology Department of our university hospital comprises data from 5586 patients diagnosed with malignant disease. Supporting Figure 1 according to the TNM 2010, T1-T4 tumor classification, and positive lymph nodes), excluding patients with distant metastasis (M1; UICC stage IVC); 3) the absence of any prior or synchronous malignancy, including squamous cell carcinoma; 4) a date of first diagnosis between 2007 and 2016 (because routine p16-positive IHC was only available since then); 5) treatment of therapy-naive OPSCC curative-intent treatment with a complete (R0) resection; and 6) a full pathohistologic report with information about the number of positive lymph nodes, lymph node status, lymph node (N) category, and ECE status (positive or negative). Consequently, patients with p16positive OPSCC who received primary, cisplatin-based, concurrent chemoradiotherapy and clinical staging only without undergoing neck dissection and therefore missing pathologic information on ECE status were excluded (n = 33) (see Supporting Fig. 1 ). The pathologist defined the presence of ECE whenever a capsule was missing (softtissue deposit; n = 3) or a disrupted lymph node capsule was visible macroscopically or microscopically (n = 59). Every patient who initially was classified according to TNM 2010 was reclassified according to TNM 2017.
The CINtec+ kit (Roche) was used for simultaneous detection of p16 and Ki67 in formalin-fixed, paraffin-embedded primary tumor samples. The detection of double-stained, p16-positive/Ki67-positive cells or a cutoff level of ≥70% p16-positive OPSCC cells was used to define positive p16 status; 41 of 92 patients with OPSCC also were analyzed on a tissue microarray to verify the heterogeneity of p16 staining.
Molecular Analyses
During panendoscopy or definitive surgery, biopsy samples of HNSCC were taken, immediately transferred into TRIzol (Invitrogen), and then stored at −80°C until mechanical disintegration of the frozen sample for 80 seconds at 4000 revolutions per minute in a Peqlab MiniLys (Peqlab), followed by isolation of DNA, as previously described. 24 HPV16 DNA status and genotype were determined in 100 ng DNA of each sample using the INNO-LiPA HPV Genotyping Extra kit (Innogenetics). 24 Patients were divided into group A (HPV16-related cancer: p16-positive/HPV16 DNA-positive) and group B (others: p16-positive/HPV16 DNA-negative, p16-positive/ other HPV DNA-positive, or discordant p16 status on IHC of full tissue slides and tissue microarray [±p16-positive], indicating inhomogeneous p16 expression), combined with ECE status. Groups A and B were further divided into group C (p16-positive/HPV16 DNA-positive/ECEnegative), group D (p16-positive/HPV16 DNA-positive/ ECE-positive), group E (±p16-positive/HPV16 DNAnegative/ECE-negative), and group F (±p16-positive/ HPV16 DNA-negative/ECE-positive), respectively.
All patients were treated according to National Comprehensive Cancer Network (NCCN) guidelines 30 by either surgery with clear margins (R0 > 5 mm) alone (Op), surgery followed by postoperative (adjuvant) radiotherapy (Op+PORT), surgery followed by postoperative (adjuvant) cisplatin-based radiochemotherapy (Op+PORCT), or induction chemotherapy followed by surgery and radiation (IC+Op+PORT). However, some patients refused the recommended adjuvant treatment or could not receive cisplatin-based PORCT ( Table 1 ).
The Ethics Committee of the Medical Faculty of the University Leipzig approved the study (votes 201-10-12072010 and 202-10-12072010). All patients provided written informed consent according to the Helsinki Declaration II.
Statistical Analysis
Statistical analyses using SPSS version 24 (IBM Corporation) included Pearson chi-square tests to assess differences between categorical variables. Timedependent covariates were measured from the date of diagnosis to the date of an event, including overall survival (OS) (the time from diagnosis to death of any cause, censoring patients who remained alive at the end of follow-up), tumor-specific survival (TSS) (the time from diagnosis to cancer-related death, censoring patients who remained alive at the end of follow-up or died from other causes), and event-free survival (EFS) (the time from diagnosis to relapse or death from any cause, censoring patients at the time of the last follow-up who remained alive without signs of any cancer). Diseasefree survival (DFS) was measured from the time of R0 resection to the date of either relapse or cancer-related death, censoring patients who remained alive at the last follow up without signs of disease. Data presented are censored at 60 months of follow-up. Alternative analyses of DFS censoring only patients who remained alive at the last follow-up and Kaplan-Meier plots for OS and TSS analyses based on the day of surgery as the starting point are available in the online Supporting Information, which also provides more detailed information on EFS, progression-free survival (PFS), local control (LC), nodal control (NC), and distant control (DC).
PFS was defined the time from diagnosis to relapse or cancer-related death censoring patients who remained alive at the end of follow-up or who died from other causes. LC was measured as the time from diagnosis to Cancer Month 0, 2020 local recurrence or second primary squamous cell carcinoma in the head and neck region, NC was measured from the time of diagnosis to locoregional relapse (focusing on positive lymph node status only), and DC was measured from the time of diagnosis to distant metastasis (M1), censoring all other PFS events. Outcome differences between groups were analyzed using Kaplan-Meier cumulative survival plots and logrank tests. Univariate and multivariate Cox regression (CoxR) analyses were used to estimate a covariate's hazard ratio (HR) and to identify independent predictors of PFS, LC, NC, DC, EFS, DFS, TSS, and OS. P values <.05 in 2-sided tests were considered significant.
RESULTS
We identified 92 patients who had lymph node-positive, p16-positive OPSCC, including 62 of 92 patients (67%) with ECE and 30 of 92 (33%) without ECE (Table 1) . Sixty-six of 92 patients (71.4%) were p16-positive/HPV16 DNA-positive, and 45 of 62 (72.6%) were ECE-positive/ p16-positive/HPV16 DNA-positive. According to the TNM 2010, 11 of 92 patients (12%) had UICC stage III disease, 78 (85%) had stage IVA disease, and 3 (3%) had stage IVB disease. The mean follow-up was 39.2 months (range, 0.8-112.5 months), the mean follow-up of survivors was 43.3 months (range, 3.8-112.5 months), and 26 patients died, including 15 from cancer-related causes and 11 from other causes (10 within 60 months of diagnosis). Local recurrences were detected in 17 of 92 patients (18.5%), nodal recurrences were detected in 5 of 92 patients (5.4%), and distant metastases were detected in 13 of 92 patients (14.1%). Within 60 months of diagnosis, these values were 16 of 92 patients (17.4%), 4 of 92 patients (4.4%), and 13 of 92 patients (14.1%), respectively.
Reclassification From the UICC TNM 2010 to TNM 2017
The reclassification from the TNM 2010 to the TNM 2017 generally revealed downstaging ( Fig. 1) Whereas TSS in patients who had ECE-negative, stage I through III OPSCC differed nonsignificantly (P = .442), significant differences in TSS were obvious in those who had ECE-positive, stage I through III OPSCC (P = .012). However, patients with stage II disease had the best TSS.
The Number of Positive Neck Lymph Nodes
Significantly higher numbers of positive lymph nodes were found in ECE-positive patients (mean, 5.0 positive lymph nodes; 95% CI, 3.8-6.4 positive lymph nodes; median, 4.0 positive lymph nodes) compared with ECE-negative patients (mean, 2.4 positive lymph nodes; 95% CI, 1.8-2.9 positive lymph nodes; median, 2.0 positive lymph nodes; P = .0007) ( Table 1; Cancer Month 0, 2020 patients had a maximum of 5 positive lymph nodes. According to receiver-operating characteristic analyses (area under the curve, 0.70; 95% CI, 0.59-0.80; P = .002), cutoff levels to predict ECE status were defined: If the number of positive lymph nodes exceeded 2.5, then ECE had to be expected (Youden index, 0.44), whereas the presence of >5 positive lymph nodes had a positive predictive value for ECE of 100% (specificity, 100%).
The Effect of ECE Status
Whereas ECE was detected in positive lymph nodes from 62 of 92 patients with OPSCC (67.4%), 30 of 92 patients (32.6%) were ECE-negative. According to chisquare tests, the clinicopathologic and demographic features of patients who had ECE-positive or ECE-negative OPSCC mostly differed nonsignificantly (Table 1) . However, positive ECE status was significantly associated with higher tumor stages (especially stage IVA and IVB [TNM 2010]; P = .037) and higher lymph node categories according to the TNM 2010 (P = .008) and the TNM 2017 (P = .019). NCCN guideline-adapted treatment led to different treatment of ECE-positive patients (P = 2.1 × 10 −5 ; eg, more Op+PORCT) ( Table 1 ).
The mean OS of patients who were included in the study was 54.9 months (95% CI, 49.4-60.4 months). Patients with ECE-positive versus ECE-negative OPSCC had an inferior OS of 49.6 months (95% CI, 42.3-56.9 months) versus 65.5 months (95% CI, 59.5-71.1 months), respectively. The mean TSS also was inferior in ECE-positive versus ECE-negative patients (57.5 months [95% CI, 50.6-64.3 months] vs 68.2 months [95% CI, 63.2-73.2 months]). Figure 2 shows ECErelated differences in the mean 5-year OS (43.0 months [95% CI, 37.4-48.7 months] vs 57.3 months [95% CI, 53.6-60.9 months]; P = .007) ( Fig. 2A ) and the mean TSS (49.0 months [95% CI, 43.8-54.2 months] vs 57.3 months [95% CI, 53.6-60.9 months]; P = .047) ( Fig. 2B ). Although T categories in patients who had p16-positive OPSCC without ECE had an insignificant impact on OS (P = .318) ( Fig. 2C ) and TSS (P = .362) ( Fig. 2D ), higher T categories impaired OS (P = .014) ( Fig. 2E ) and TSS (P = .007) ( Fig. 2F ) in patients who had p16-positive OPSCC with ECE. Alternative analyses choosing the day of resection as the starting point confirmed these observations (see Supporting Fig. 3) .
In contrast to positive ECE status ( Fig. 2A,B) , the number of positive lymph nodes stratified according to N categories of the TNM eighth edition (TNM 2017) showed no significant differences in OS (P = .935) or TSS (P = .410) (compare with Supporting Fig. 8) and clustered related to ECE status, not N categories (Fig. 2G,H) ; indeed, positive ECE status, rather than N category, was linked to impaired OS and TSS. The significantly lower DFS, EFS, and PFS of patients who had p16-positive OPSCC with positive ECE status are in line with these findings (see Supporting Information).
The Effect of HPV16 DNA Negativity and/or Heterogeneous p16 Expression
In our cohort of 92 patients with p16-positive OPSCC, only 66 (71.7%) had HPV16-related OPSCC (p16positive/HPV16 DNA-positive; group A), and 26 of 92 (28.3%) were classified as others (group B). Group B included 1 patient who was positive for HPV18 DNA (1.1%), 22 patients (23.9%) who were without detection of any HPV DNA, and 3 patients (3.3%) with HPV16 DNA-positive OPSCC who had heterogeneity for p16 on IHC (±p16). According to the Kaplan-Meier plots, group A had slightly improved 5-years OS and TSS (P = .162 and P = .168, respectively). Related to significant improved NC (P = .030); in particular, DC (P = .003), PFS (P = .046), DFS (P = .044), and EFS (P = .022) were improved in HPV16 DNA-positive versus other p16positive OPSCCs (see Supporting Fig. 7) .
Analyses limited to group A (the 66 patients with p16-positive/HPV-positive disease) ( Fig. 3 ) also revealed a significant impact of ECE on OS (P = .013), TSS (P = .026), and EFS (P = .025); and a trend was observed with respect to DFS (P = .051) and PFS (P = .052). With EFS as the only exception, the Kaplan-Meier plots for patients with ECE-negative/ p16-positive/HPV16-positive OPSCC never reached the 75th percentile, demonstrating superior outcomes for patients with ECE-negative, p16-positive, HPVpositive OPSCC. . For TSS, differences in outcome were insignificant (P = .106), but the patients in group C (HPV16D NA-positive/ECE-negative) had improved survival compared with those in groups D, E, and F. Significant differences in DFS (P = .021), PFS (P = .021), and EFS (P = .001) were observed ( Fig. 4 ). More information is provided in the online Supporting Information (see Supporting Fig. 6 ). Overall, the poorest outcome was observed in patients who had ECE-positive/p16-positive OPSCC without detectable HPV16.
Cox Proportional Hazard Models
The HRs and 95% CIs from univariate CoxR consistently revealed that ECE was a significant independent predictor of impaired OS (HR, 3.400; 95% CI, 1.169-9.890; P = .025), DFS (HR, 3.007; 95% CI, 1.144-7.904; P = .026), EFS (HR, 3.536; 95% CI, 1.471-8.500; P = .005), and PFS (HR, 3.012; 95% CI, 1.146-7.918; P = .025). TSS (HR, 4.045; 95% CI, 0.910-17.97; P = .066), LC (HR, 2.902; 95% CI, 0.830-10.14; P = .095), NC (HR, 2.699; 95% CI, 0.298-24.47; P = .378), and DC (HR, 1.458; 95% CI, 0.447-4.753; P = .531) also were increased in patients who were positive for ECE.
In separate analyses of the 66 patients with p16-positive/HPV16-positive OPSCC (group A), ECE was a significant predictor of impaired OS (HR, 8 Multivariate CoxR using the stepwise forward method were used to assess the effect on OS, TSS, DFS, and PFS (Fig. 5 ) of covariates of P < .2 in univariate analyses. These factors included categorical covariates, localization (ICD-10 code C09 vs others), ECE status (positive vs negative), HPV16-negative status (other than p16-positive/HPV-positive), tumor (T) category (T1-T3 vs T4), alcohol consumption (≠0, ≤30 vs 0, >30 grams per day), smoking (≤28 vs >28 pack-years; the median of pack-years observed in the cohort of 415 patients with OPSCC) (see Supporting Fig. 1 ), therapy (Op+PORCT vs other), and (as a continuous variable) the number of positive lymph nodes. Related to correlation or confounding, age, sex, UICC stage according to the TNM 2017 or the TNM 2010, and time to intervention (the interval between diagnosis and the start of therapy) were not identified as independent predictors in any model.
The final model for OS that achieved the highest significance (Pearson chi-square test, 16.09 with 3 degrees of freedom (df ); P = .001) included 3 independent predictors: T category (T4 vs T1-T3: HR, 2.308; 95% CI, 1.041-5.118; P = .040), ECE status (ECEpositive vs ECE-negative: HR, 3.209; 95% CI, 1.100-9.363; P = .033), and alcohol consumption (0 or >30 vs <30 grams per day: HR, 2.498; 95% CI, 0.984-6.341; P = .054). Localization, therapy, HPV16-negative status, the number of positive lymph nodes, and smoking were not identified as independent predictors for OS (P > .2).
The 
DISCUSSION
In our cohort of primarily surgically treated patients with lymph node-positive/p16-positive OPSCC, the positive detection of ECE was consistently identified as a significant independent predictor for reduced OS, DFS, and PFS in all Kaplan-Meier plots applying log-rank tests ( Figs. 1-4 ; see Supporting Figs. [3] [4] [5] [6] [7] [8] , and univariate and multivariate CoxR analyses (Fig. 5 ) demonstrated poor outcomes for patients who were positive for ECE. Moreover, positive ECE status was one leading reason for inexact prognostication of survival in our cohort (Fig. 1) .
Staging systems like the TNM classification in oncology should express the level and extension of disease and provide an easy-to-obtain and user-friendly estimate for prognosis, simplifying decision-making for the appropriate therapy modalities. To support comparability between outcomes, specific groups of cases should be separated to facilitate comparability, for instance, within studies. 32 In 2002, four criteria characterizing an appropriate staging system and essentially required to convincingly distinguish groups were defined by Groome et al 32, 33 : 1) hazard consistency: patients within a group (stage) must have similar survival rates; 2) hazard discrimination: perceptible differences in survival rates exist between the groups; 3) outcome prediction: high prediction of similar cure rates within a group; and 4) balanced distribution of patients among the groups. Furthermore, a good staging system should be user-friendly and consistent across time, and it should give an indication of prognosis. 33 Based on 1907 patients with HPV-related OPSCC (either p16-positive or HPV-positive on in situ hybridization) who were treated nearly exclusively by radiotherapy with or without chemotherapy, the multinational International Collaboration on Oropharyngeal Cancer Network for Staging proposed a superior staging system for p16-positive OPSCC. 34 Consequently, in the TNM 2017 (eighth edition), the separate staging of p16-positive OPSCC was introduced because positive p16 status (provided by NCCN-adapted, guideline-conformed treatment) defines a specific group of patients with OPSCC who, compared with p16-negative OPSCC patients, have a lower impact of higher T and N categories (especially the number of positive lymph nodes) on outcome. 34 We also detected a lower impact of T and N categories in our cohort of patients with p16-positive OPSCC, but also detected an impact of ECE. Given the methodological differences an impact of ECE on outcome could not be detected in their study because only 4 of 661 patients (1%) in their training cohort and 30 of 1246 (2%) p16-positive OPSCC patients in their validation cohort reportedly were treated primarily by surgery. However, the prognostic prediction in our p16-positive OPSCC cohort failed because patients with stage II disease according to the TNM 2017 had better OS and TSS than those with stage I and III (Fig. 1) , and the improved outcome according to the TNM 2017 was limited to the group without ECE. Reasons for this may be increased frequency of local recurrence and a stronger impact of higher T categories in patients who had p16-positive OPSCC with positive ECE status (Fig. 2) .
We explain this discrimination problem of the TNM 2017 as follows: because we focused on ECE status and thus excluded lymph node-negative (N0) cases, stage I included only T1-T2N1 disease (1-4 positive lymph nodes), and UICC stage II is either T3N1 or T1-T2N2 (≥5 positive lymph nodes) disease, whereas UICC stage III is T3N2 or T4N1-N2 disease. A high frequency of positive ECE status was detected in patients who had stage I (20 of 36; 55.6%), stage II (18 of 26; 69.2%), and stage III (24 of 30; 80%) disease. Moreover, an uneven distribution of death events was observed in patients who had stage I (9 of 36 patients; 25%), stage II (3 of 26 patients; 11.5%), and stage III (14 of 30 patients; 46.7%) disease. Death events were associated with the presence of ECE: 22 of 26 (84.6%) and only 4 of 26 (15.4%) death events occurred in ECE-positive and ECE-negative patients, respectively, Cancer Month 0, 2020 corresponding to 22 of 62 (35.5%) ECE-positive patients and 13 of 30 (13.3%) ECE-negative patients; 6 of 20 patients (30%) and 13 of 24 patients (54.2%) who had ECE-positive OPSCC died in stages I and III, respectively. Because death events in patients with stage I disease who had only 1 positive lymph node occurred exclusively if that lymph node was positive for ECE and measured >3 cm (formerly classified as N2a), and because only 3 of 18 patients (16.7%) who had ECE-positive stage II disease (initially categorized as N3 [1 of 3 patients] and N2b [2 of 3 patients], both with a maximum dimension >3 cm) died, the volume of ECE-positive/lymph node-positive disease also may not be completely unimportant in p16-positive OPSCC. Although standardized neck dissection procedures seem to be able to obliterate the expected difference between N1 and N2 regarding prognosis, the presence of ECE, even if observed in only 1 positive lymph node, overwhelms differences related to the numbers of positive lymph nodes and, hence, the categories N1 and N2 (Fig. 2) . This is in full agreement with the findings of Lewis et al 35 in a cohort of surgically treated patients, most of whom (90 of 101; 89%) had p16-positive OPSCC. Among 63 patients who had grade 2-4 ECE (equal to ECE-positive in our cohort) and 38 who had grade 0 and 1 ECE (no ECE in our cohort), significantly reduced ECE-related OS (P = .03) and DFS (P = .007) were reported. 35 In univariate CoxR analyses of OS, DFS, EFS, and PFS in 92 patients who had p16-positive OPSCC with full information about ECE and HPV status, positive ECE status was identified as an independent predictor for decreased survival. The ECE-associated HRs for OS (HR, 3.40; P = .025), DFS (HR, 3.01; P = .026), EFS (HR, 3.54; P = .005), and PFS (HR, 3.01; P = .025) demonstrate consistently a 3 to 4 times increased risk of events, including death whenever ECE is detected in at least 1 positive lymph node. The HRs for TSS, LC, NC, and DC were insignificant given the low case numbers but indicated a strongly decreased outcome (HR, between 1.6 and 4.0).
Analyses limited to the 66 p16-positive/HPVpositive patients demonstrated significant HRs for events in EFS and OS and, again, increased but insignificant HRs for DFS, PFS, LC, and DC, probably caused by the lower number of events and wider CIs. ECE-positive status and HPV16 DNA-negative status were the leading predictors for inferior survival (OS, TSS, EFS, and PFS) in the 4 groups C to F (Fig. 4) .
Multivariate CoxR, and especially bootstrapping, revealed positive ECE status as predictor of impaired survival in patients with p16-positive OPSCC, and its impact was independent from confounding: All models consistently demonstrated that ECE was independent predictor for decreased OS (P = .033), TSS (P = .165), PFS (P = .042), and DFS (P = .040), confirming the results from Kaplan-Meier analyses, with log-rank tests showing significantly impaired OS (P = .013), TSS (P = .026), PFS (P = .052), and DFS (P = .051). Compared with survival data for p16-positive OPSCC from the United States, outcomes in our cohort appear to be poorer and closer to the outcomes of patients with p16-negative OPSCC; therefore, the first and second criterion from Groome et al, 32 hazard consistency within the subgroup and hazard discrimination between groups, failed. Regarding risk-factor distribution, our cohort is much closer to patients with p16-negative versus p16-positive OPSCC from US cohorts. Indeed, our cohort is characterized by much higher levels of alcohol consumption and life-time history of smoking, older age, and advanced disease, with T3 and T4 tumors in approximately one-quarter of patients each (Table 1) .
Independent from the higher survival rates and lower absolute differences between ECE-negative and ECE-positive patients, data from the American National Cancer Data Base support our findings. An et al 36 The ECE-associated HR for outcome in our study and in the above-mentioned US cohorts do not deviate significantly and, all together, link ECE in patients with p16-positive OPSCC to impaired outcome. According to these results and despite numerous studies stating an insignificant prognostic impact of ECE in p16-positive OPSCC, [39] [40] [41] [42] [43] [44] it is questionable whether the omitted inclusion of ECE in the definition of N categories and staging of p16-positive OPSCC in the TNM 2017 is appropriate. However, ECE is known as risk factor for outcome because it was consistently associated with an increased risk of recurrence, 45 loss of DC, 28, 29, 37 and decreased survival. 46 Consequent to findings in the milestone trials from Cooper et al and Bernier et al, 29, 31, 47 the detection of ECE (or residual disease [R1], or close margins <5 mm after R0 resection) requires adjuvant cisplatin-based chemoradiation (PORCT) in patients with OPSCC. Therefore, the NCCN guidelines considered ECE as a high-risk factor defining the need for PORCT independent from p16 status. 30 Fortunately, to date, the new TNM 2017 has not led to changes in treatment decisions, which, at least in Germany, adhere to the NCCN guidelines stratifying treatment according to T, N, and M categories as well as positive ECE status, but not UICC stage.
Based on findings in clinical phase III trials and registries in the United States, the new TNM 2017 discriminates 2 independent types of OPSCC using p16 as surrogate marker for HPV-associated cancer. However, the TNM 2017 does not exactly define the requirements for using the method adequately for the enumeration of p16-positive cells to assess p16 status. In addition, the reagents to detect p16 reliably are not declared. The CINtec+ kit is broadly accepted and allows for the detection of p16-positive OPSCC using either a cutoff level ≥50% of p16-positive cells or the detection of cells double-stained for the p16 and Ki67 proteins (HPV-driven cells). 48 In contrast, some studies emphasize that HPV16 RNA E6*I is superior to p16 INK4A as a determining factor for HPV-related cancer because it is a marker of transcriptionally active infection. 23, 24 Conspicuous was the dependence, especially of DFS, PFS, LC, NC and DC, on HPV16 DNA-negative status as well as HPV16 DNA-negative status combined with positive ECE status. The grouping of our cohort into those with HPV16 DNA-positive/ECE-negative (group C), HPV16 DNA-positive/ECE-positive (group D), HPV16 DNA-negative/ECE-negative (group E), and HPV16 DNA-negative/ECE-positive (group F) OPSCC demonstrated superior outcome discrimination ( Fig. 4 ; see Supporting Fig. 7 ). Positive HPV16 DNA status was predictive for improved DFS, PFS, NC, and DC, but positive ECE status remained an independent predictor for inferiority ( Fig. 5 ). Consistently, positive ECE status and negative HPV16 DNA status predicted an impaired outcome in multivariate CoxR.
According to published reports and our own data on the correlation between HPV status and p16 IHC, >10% each of HPV-related OPSCCs (HPV DNApositive/HPV RNA-positive) and non-HPV-related OPSCCs (HPV DNA-negative/RNA-negative and HPV DNA-positive/HPV RNA-negative) are expected to be false-negative or false-positive, respectively, and lower the prognostic value of positive p16 status. In the current sample, 23.9% of patients with p16-positive OPSCC were without detectable HPV DNA, in line with 17% HPV DNA-negative/p16-positive OPSCC reported in the Netherlands. 49 Because patients who had p16-positive OPSCC without detectable HPV16 DNA had inferior outcomes compared with the good outcomes of those who had p16-positive/HPV-positive OPSCC ( Fig. 4 ; see Supporting Fig. 7) , HPV genotyping may improve prognostic staging.
Limitations of our study were its retrospective character, the small number of 92 patients, and the inclusion only of patients with surgical resected, advanced OPSCC according to the TNM 2010. Therefore, our statement regarding the prognostic accuracy of the TNM 2017 and survival data only pertains to (formerly) advanced-stage OPSCC and does not apply to earlier stages. However, because our cohort represents patients with p16-positive OPSCC who had changes in their staging, and because outcome prediction is most critical, the low number of 92 patients also allowed us to detect the significant effects of ECE and HPV16 status on most outcome parameters analyzed. For various reasons, 148 of 415 lymph node-positive patients with OPSCC, including 59 who underwent R0 resection, could not be analyzed for p16 expression and did not undergo HPV detection and genotyping. Consequently, our analyses represent 81.9% of patients who underwent R0 resection for OPSCC and, all things being equal, approximately 81.9% patients with p16-positive OPSCC were eligible for the study.
The current study has several strengths. The monocentric character of this study led to a uniform frame regarding diagnostic methods and therapy modalities, following the same processes and decision-making methods used in our tumor board. The availability of data on surgical therapy and R0 resection, full information about p16 expression and HPV DNA detection, the number of positive lymph nodes, ECE status, levels of alcohol consumption and available smoking history, our complete data set without missing information allowed for comprehensive outcome assessment. The standardized follow-up allowed for a reliable examination of OS, TSS, DFS, EFS, PFS, LC, NC and DC.
Conclusions
Positive ECE status and negative HPV16 DNA status affect the survival of patients who have p16-positive OPSCC. Both are independent predictors in p16-positive OPSCC but, to date, have been omitted in staging according to the TNM 2017. Both are among potential reasons why TNM 2017 staging was unable to provide an exact indication of prognosis 33 in our cohort of patients with surgically treated, p16-positive OPSCC. At least in this German cohort, the TNM 2017 failed to appropriately address the 4 criteria characterizing an appropriate staging system: 1) hazard consistency, 2) hazard discrimination, 3) outcome prediction, and 4) balanced distribution of patients among the groups. 32, 33 Therefore, the TNM 2017 does not allow for a uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive OPSCC. As long as sufficient consideration of ECE and HPV16 status is missing, a revision of the UICC staging system for primarily surgically treated patients with p16positive OPSCC and the inclusion of these biomarkers, which exert an essential effect on outcome, appears to be required to overcome the limitations of the TNM 2017. Rather, outside of randomized clinical trials, the treatment of p16-positive OPSCC should adhere to the current (unmodified) NCCN guidelines.
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